B-PO05-136 ANTI-CANCER THERAPY INDUCED ATRIAL FIBRILLATION - A PHARMACOVIGILANCE ANALYSIS

Abstract

Certain anti cancer therapies have been associated with new onset AF. The FDA Adverse Event Reporting System (FAERS) is a publicly available database of adverse events (AE) of various drugs. To identify anti-cancer drugs associated with AF using FAERS. FAERS database was searched for all drugs reporting AF as an adverse event. Top 30 anti-cancer drugs reporting AF cases were shortlisted and analyzed. Top three anticancer drugs for each assessment of AF are given in the table. Lenalidomide had the largest number of AF cases reported for any anti-cancer drug (2363; 3.2% of all AF cases reported to FAERS), Ibrutinib (2138 cases; 2.9% of all AF reported to FAERS) had the largest proportion of AF of all reported cardiovascular AE for the drug (41.5%) and the second largest proportion of AF of all reported AE for the drug (5.3%). Among all deaths reported for a drug, Ibrutinib had the highest proportion of patients who had AF. The proportion of AF patients who died were lower for ibrutinib compared to other anti-cancer drugs. The comparative mortality ratio for death with AF is the lowest for Ibrutinib. The largest proportion of AF of all reported AE for any anti-cancer drug was for Nivolumab (5.7%). 24% of AF patients reported for the drug died. Prospective studies are needed to better understand the true incidence of new onset AF associated with chemotherapeutic drugs.